Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an announcement.
Hemogenyx Pharmaceuticals announced the exercise of warrants over 250,000 new ordinary shares, resulting in the issuance of equity and receipt of £450,000 in subscription monies. This development will increase the total number of issued shares to 5,293,896, impacting shareholder voting rights and potentially enhancing the company’s financial position as it continues its clinical trials.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded biopharmaceutical company based in London, with operations in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, leveraging distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 77,912
Technical Sentiment Signal: Buy
Current Market Cap: £43.02M
See more insights into HEMO stock on TipRanks’ Stock Analysis page.